drugset / Trial / NCT00271804
Study of Velcade and Thalidomide in Patients With Myelodysplasia
Phase 1
Terminated
28 enrolled
Massachusetts General Hospital
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabDana-Farber Cancer Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what the maximal tolerated dose of Velcade can be given with thalidomide in patients with myelodysplasia.
Timeline
- Start
- 2005-06
- Primary completion
- —
- Completion
- 2007-04
Outcome
Outcome not reported
Stopped: “New study with lenalidomide pending”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 0.7 mg/m2 | — |
| Subject | Bortezomib | Small molecule | 1 mg/m2 | — |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |